By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 120.93 |
Change Today | $ -0.15 |
% Change | -0.12 % |
52 Week High | $236.72 |
52 Week Low | $118.15 |
Volume | 2,332,604 |
Shares Issued | 145.80m |
Market Cap | $17,632m |
RiskGrade | 259 |
Strong Buy | 6 |
Buy | 9 |
Neutral | 20 |
Sell | 0 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
16:00 | 1,000 @ $120.97 |
16:00 | 258,622 @ $120.93 |
15:59 | 212 @ $121.02 |
15:59 | 150 @ $121.02 |
15:59 | 963 @ $121.01 |
You are here: research